ARTICLE | Clinical News
Dendreon completes first Provenge Phase III
September 6, 2001 7:00 AM UTC
DNDN completed patient enrollment in its first Phase III study of Provenge activated autologous dendritic cell therapy to treat advanced hormone resistant prostate cancer. Data from the trial are expe...